Information Provided By:
Fly News Breaks for February 5, 2020
VYGR
Feb 5, 2020 | 16:11 EDT
As previously reported, Oppenheimer analyst Jay Olson initiated coverage of Voyager Therapeutics with an Outperform rating and $26 price target. He sees significant commercial potential for its Parkinson's Disease gene therapy VY-AADC, which he expects to have potentially significant advantages over Deep Brain Stimulation, Olson tells investors. He estimates a 50% probability of success for the pivotal RESTORE-1 and -2 trials, the analyst added.
News For VYGR From the Last 2 Days
There are no results for your query VYGR